Patient Stories
Advancing Targeted Cancer Therapy Selection Through Liquid Biopsy | Dr. Gilberto Lopes
Dr. Gilberto Lopes, Chief of the Division of Medical Oncology and Associate Director of the Sylvester Comprehensive Cancer Center at the University of Miami, explores the evolving landscape of targeted therapy and how liquid biopsy — combining ctDNA and ctRNA analysis — supports personalized treatment planning.
LiquidHALLMARK® by Lucence is an ultra-sensitive liquid biopsy test that analyzes ctDNA and ctRNA to enable tailored treatment decisions. Speak to your healthcare provider to seek advice on your options.
Our Flagship Solutions
Everyone deserves to live longer, healthier and with greater peace of mind.
Powered by our proprietary AmpliMARK™ technology, our solutions deliver insights tailored to your needs.
About Us
Earlier Detection. Better Health.
What if health conditions could be detected earlier before symptoms show up, when prevention is possible?
At Lucence, we believe that earlier detection is the key to longevity by advancing detection before symptoms even appear. Our ultrasensitive tests deliver insights to guide doctors in providing you with a personalized health action plan.
Everyone’s story is unique. Our wide range of tests aim to provide a test that fits into everyone’s story. We are here with you at every step of your health journey.
News & Updates
